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Despite the advent of echinocandins and newer triazoles (voriconazole, posacona-zole, and isavuconazole) (1), fluconazole (FLZ) remains an important component of
today’s antifungal arsenal, particularly for treatment of Candida infections (2, 3). How-
ever, FLZ may not be effective against Candida species, including C. albicans and (more
frequently) C. glabrata, in cases of azole-resistant isolates (4). Except in C. krusei (a
Candida species that is intrinsically FLZ resistant), the general and long-term therapeu-
tic use of FLZ (or other triazoles) can result in acquisition of molecular mechanisms that
enable Candida isolates to exhibit antifungal resistance (5). It is known that increased
drug efflux pump activities result in low intracellular azole accumulation, while muta-
tions in the 14--lanosterol demethylase—the primary fungal target—prevent azoles
from enzyme binding (6). Fenticonazole (FEZ) is an imidazole-derived antifungal com-
pound that, unlike triazoles, displays in vitro antimicrobial activity not only directed
against fungal isolates (7). Thus, a peculiar FEZ mechanism of action—perhaps related
to its oxidative cytotoxicity— could allow the drug not only to cure mixed fungal and
bacterial infections (8) but also to overcome the main ways in which Candida species
may acquire antifungal resistance (6).
We tested the activity of FEZ against paired isolates (i.e., parental and derivative
isolates) from C. albicans (20 isolates) and C. glabrata (30 isolates) species, respectively.
In each isolate’s pair, the FLZ-resistant (derivative) isolate originated from the FLZ-
susceptible or susceptible-dose-dependent (parental) isolate following resistance de-
velopment during patient infection (9). All except four (from bloodstream infection)
isolates were from mucosal surface (e.g., oropharyngeal, vaginal, etc.) infections. All 25
FLZ-resistant (10 C. albicans and 15 C. glabrata) isolates exhibit known molecular
resistance mechanisms, which consisted of upregulation of drug efflux pump-encoding
genes (CDR1/CDR2, MDR1 [only for C. albicans], and SNQ2 [only for C. glabrata]) and/or
point mutations of 14--lanosterol demethylase-encoding ERG11 gene (Table S1 in the
supplemental material). MIC values to FEZ and FLZ— both obtained as standard
powders from Sigma-Aldrich (Milan, Italy)—were determined using the protocol spec-
ified in the Clinical and Laboratory Standards Institute (CLSI) M27-A3 document without
modifications (10). Only for FLZ, MIC values were interpreted according to species (C.
albicans or C. glabrata)-specific clinical breakpoints reported in the CLSI M27-S4 doc-
ument (11). We used MIC values (Table S1) to calculate geometric mean (GM) MICs with
95% confidence intervals (CIs) and MIC ranges for both FEZ and FLZ antifungal drugs.
We assessed statistically significant (P  0.05) differences between GM MIC values
obtained for isolate groups from each species (see below), using repeated-measures
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analysis of variance (ANOVA) on log2 MICs followed by Bonferroni-Dunn’s multiple-
comparison test (12).
Of 25 isolates with molecular mechanisms contributing to the FLZ resistance
phenotype observed in vitro, 15 C. glabrata and 1 C. albicans isolate overexpressed drug
efflux pumps alone, whereas 9 C. albicans isolates combined overexpression of drug
efflux pumps and ERG11 amino acid substitution(s) (Table S1). For C. albicans isolates,
FEZ MIC ranges were 0.25 to 2 mg/liter among FLZ-nonresistant isolates (MICs, 0.125 to
1 mg/liter) and 1 to 8 mg/liter among FLZ-resistant isolates (MICs, 16 to 256 mg/liter).
For C. glabrata isolates, FEZ MIC ranges were 0.5 to 2 mg/liter among FLZ-nonresistant
isolates (MICs, 2 to 16 mg/liter) and 0.5 to 4 mg/liter among FLZ-resistant isolates (MICs,
64 to 256 mg/liter). Figure 1 shows the distribution of FEZ MICs in the FLZ-nonresistant
or resistant isolates of C. albicans and C. glabrata, respectively. Interestingly, the GM
MICs  CIs of C. albicans FEZ MICs in FLZ-nonresistant isolates differed significantly
from that in FLZ-resistant isolates (GM MIC of 0.65 [95% CI, 0.40 to 1.06] versus GM MIC
of 3.03 [95% CI, 1.87 to 4.89]; P  0.001). Conversely, no significant difference was seen
between the GM  CIs of C. glabrata FEZ MICs in FLZ-nonresistant isolates and that in
FLZ-resistant isolates (GM MIC of 0.83 [95% CI, 0.63 to 1.08] versus GM MIC of 1.66 [95%
CI, 1.22 to 2.25]; P  0.26).
In conclusion, we showed that FEZ MIC values were lower than FLZ MIC values in 50
well-characterized isolates from two clinically relevant Candida species, including C.
albicans and C. glabrata. Remarkably, differences were more prominent in FLZ-resistant
isolates than their nonresistant counterparts but were statistically significant only for C.
albicans. Our data demonstrate that FEZ exhibits higher activity than FLZ. FEZ activity
was less dependent on drug efflux pump-mediated FLZ resistance in Candida species
such as C. glabrata. Based on these findings, FEZ should be evaluated as a candidiasis
treatment, particularly in patients with recurrent or antifungal-recalcitrant Candida
infections.
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FIG 1 Distribution of FEZ MICs for clinical C. albicans and C. glabrata isolates without (nonresistant [non-R] isolates) or with (resistant
[R] isolates) molecular mechanisms contributing to FLZ resistance phenotype. Shown is the presence or absence of statistical
significance (P  0.001; NS, no significance) between the FEZ GMs of isolate groups represented by a horizontal line within each plot,
which displays individual FEZ MIC points. Error bars indicate confidence intervals.
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